Lilly to Acquire Merida Biosciences for $2.9B to Enhance Immune Drug Pipeline
Deals·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Lilly has announced its acquisition of Merida Biosciences for $2.9 billion, aiming to advance treatments for serious autoimmune and allergic diseases. This deal marks Lilly's latest effort to bolster its drug pipeline focused on immune-related conditions, including Graves' disease.
The acquisition is part of Lilly's strategy to enhance its offerings in the biopharmaceutical sector, specifically targeting serious autoimmune and allergic diseases. The move is expected to significantly strengthen Lilly's position in the market for immune therapies.
LillyMerida Biosciences
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases”
SEC Filing — Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases“<figure><div><img”
biopharma dive — Lilly adds to immune drug pipeline with $2.9B Merida buyout